Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease in the world. It encompasses a histological spectrum, ranging from simple, nonprogressive steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis and hepatocellular carcinoma. While liver-related complications are confined to NASH, emerging evidence suggests both simple steatosis and NASH predispose to type 2 diabetes and cardiovascular disease. The pathogenesis of NAFLD is currently unknown, but accumulating data suggest that oxidative stress and altered redox balance play a crucial role in the pathogenesis of steatosis, steatohepatitis, and fibrosis. We will examine intracellular mechanisms, including mitochondrial dysfunction and impaired oxidative free fatty acid metabolism, leading to reactive oxygen species generation; additionally, the potential pathogenetic role of extracellular sources of reactive oxygen species in NAFLD, including increased myeloperoxidase activity and oxidized low density lipoprotein accumulation, will be reviewed. We will discuss how these mechanisms converge to determine the whole pathophysiological spectrum of NAFLD, including hepatocyte triglyceride accumulation, hepatocyte apoptosis, hepatic inflammation, hepatic stellate cell activation, and fibrogenesis. Finally, available animal and human data on treatment opportunities with older and newer antioxidant will be presented. Antioxid. Redox Signal. 15, 1325–1365.
AggarwalBB, HarikumarKB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol, 41:40–59. 2008.
5.
AggarwalBB, SungB. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci, 30:85–94. 2009.
6.
AlameddineFM, ZafariAM. Genetic polymorphisms and oxidative stress in heart failure. Congest Heart Fail, 8:157–164. 2002.
7.
AlwaynIP, AnderssonC, ZauscherB, GuraK, NoseV, PuderM. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation, 79:606–608. 2005.
8.
AmesBN, ShigenagaMK, HagenTM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA, 90:7915–7922. 1993.
9.
AnandP, KunnumakkaraAB, NewmanRA, AggarwalBB. Bioavailability of curcumin: problems and promises. Mol Pharm, 4:807–818. 2007.
10.
AokiH, KangPM, HampeJ, YoshimuraK, NomaT, MatsuzakiM, IzumoS. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem, 277:10244–10250. 2002.
11.
AoyamaT, PetersJM, IritaniN, NakajimaT, FurihataK, HashimotoT, GonzalezFJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)J Biol Chem, 273:5678–5684. 1998.
12.
AragnoM, TomasinelliCE, VercellinattoI, CatalanoMG, CollinoM, FantozziR, DanniO, BoccuzziG. SREBP-1c in NAFDL induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med, 47:1067–1074. 2009.
AuboeufD, RieussetJ, FajasL, VallierP, FreringV, RiouJP, StaelsB, AuwerxJ, LavilleM, VidalH. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes, 46:1319–1327. 1997.
17.
BarberaMJ, SchluterA, PedrazaN, IglesiasR, VillarroyaF, GiraltM. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem, 276:1486–1493. 2001.
18.
BastardJP, MaachiM, LagathuC, KimMJ, CaronM, VidalH, CapeauJ, FeveB. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw, 17:4–12. 2006.
19.
BellwardGD, ChangT, RodriguesB, McNeillJH, MainesS, RyanDE, LevinW, ThomasPE. Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. Mol Pharmacol, 33:140–143. 1988.
20.
BergaminiCM, GambettiS, DondiA, CervellatiC. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des, 10:1611–1626. 2004.
21.
BersonA, De BecoV, LettéronP, RobinMA, MoreauC, El KahwajiJ, VerthierN, FeldmannG, FromentyB, PessayreD. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 117:764–774. 1998.
22.
BidlackWR, BrownRC, MohanC. Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity. Fed Proc, 45:142–148. 1986.
23.
BlanckJ, RistauO, ZhukovAA, ArchakovAI, ReinH, RuckpaulK. Cytochrome P-450 spin state and leakiness of the monooxygenase pathway. Xenobiotica, 21:121–135. 1991.
24.
BlasioleDA, OlerAT, AttieAD. Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB. J Biol Chem, 283:11374–11381. 2008.
25.
BodenG, DuanX, HomkoC. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes, 57:2438–2444. 2008.
26.
BoltHM, RoosPH, TheirR. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health, 76:174–185. 2003.
27.
BothamKM, ZhengX, NapolitanoM. The effects of dietary n-3 polyunsaturated fatty acids delivered in chylomicron remnants on the transcription of genes regulating synthesis and secretion of very-low-density lipoprotein by the liver: modulation by cellular oxidative state. Exp Biol Med, 228:143–151. 2003.
28.
BrownKE, BruntEM, HeineckeJW. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol, 159:2081–2088. 2001.
CaballeroF, FernándezA, De LacyAM, Fernández-ChecaJC, CaballeríaJ, García-RuizC. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatology, 50:789–796. 2009.
32.
CaiD, YuanM, FrantzDF, MelendezPA, HansenL, LeeJ, ShoelsonSE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 11:183–190. 2005.
CanoA, CiaffoniF, SafwatGM, AspichuetaP, OchoaB, BravoE, BothamKM. Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver disease: is there a role for dietary coenzyme Q?J Appl Physiol, 107:707–717. 2009.
35.
CaroJF, KolaczynskiJW, NyceMR, OhannesianJP, OpentanovaI. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet, 348:159–161. 1996.
36.
Carter-KentC, ZeinNN, FeldsteinAE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol, 103:1036–1042. 2008.
ChavinKD, YangS, LinHZ. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem, 274:5692–5700. 1999.
41.
ChenC, DudenhausenEE, PanYX, ZhongC, KilbergMS. Human CCAAT/enhancer-binding protein beta gene expression is activated by endoplasmic reticulum stress through an unfolded protein response element downstream of the protein coding sequence. J Biol Chem, 279:27948–27956. 2004.
42.
ChenJ, SchenkerS, FrostoTA, HendersonGI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta, 1380:336–344. 1998.
ChoiCS, SavageDB, Abu-ElheigaL, LiuZX, KimS, KulkarniA, DistefanoA, HwangYJ, ReznickRM, CodellaR, ZhangD, ClineGW, WakilSJ, ShulmanGI. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci USA, 104:16480–16485. 2007.
45.
CookGA, GambleMS. Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. J Biol Chem, 262:2050–2055. 1987.
46.
Cortez-PintoH, ChathamJ, ChackoVP, ArnoldC, RashidA, DiehlAM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA, 282:1659–1664. 1999.
47.
Cortez-PintoH, Zhi LinH, Qi YangS, OdwinDA, CostaS, DiehlAM. Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology, 116:1184–1193. 1999.
48.
DallaireP, BellmannK, LaplanteM, GélinasS, Centeno-BaezC, PenfornisP, PeyotML, LatourMG, LamontagneJ, TrujilloME, SchererPE, PrentkiM, DeshaiesY, MaretteA. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. Diabetes, 57:1999–2011. 2008.
49.
DavisRJ. Signal transduction by the JNK group of MAP kinases. Cell, 103:239–252. 2000.
50.
DayCP, JamesOFW. Steatohepatitis: A tale of two hits. Gastroenterology, 117:842–845. 1998.
51.
De la LastraCA, VillegasI. Resveratrol as an anti-inflamatory and anti-aging agent: mechanisms an clinical implications. Mol Nutr Food Res, 49:405–430. 2005.
52.
DeleriveP, De BosscherK, BesnardS, Vanden BergheW, PetersJM, GonzalezFJ, FruchartJC, TedguiA, HaegemanG, StaelsB. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem, 274:32048–32054. 1999.
53.
DemeilliersC, MaisonneuveC, GrodetA, MansouriA, NguyenR, TinelM, LetteronP, DegottC, FeldmannG, PessayreD, FromentyB. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology, 123:1278–1290. 2002.
54.
DesvergneB, WahliW. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 20:649–688. 1999.
55.
DevchandPR, KellerH, PetersJM, VazquezM, GonzalezFJ, WahliW. The PPAR-alpha-leukotriene B4 pathway to inflammation control. Nature, 384:39–43. 1996.
56.
DeyA, CederbaumAI. Induction of cytochrome P450 2E1 promotes liver injury in ob/ob mice. Hepatology, 45:1355–1365. 2007.
57.
DiehlAM. Lessons from animal models of NASH. Hepatol Res, 33:138–144. 2005.
58.
DiesenDL, KuoPC. Nitric oxide and redox regulation in the liver. Part I. General considerations and redox biology in hepatitis. J Surg Res, 162:95–109. 2010.
59.
DonnellyKL, SmithCJ, SchwarzenbergSJ, JessurunJ, BoldtMD, ParksEJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest, 115:1343–1351. 2005.
60.
DringenR. Metabolism and functions of glutathione in brain. Progr Neurobiol, 62:649–671. 2000.
61.
DrogeW. Free radicals in the physiological control of cell function. Physiol Rev, 82:47–95. 2002.
62.
DufourJF, OnetaCM, GonversJJ, BihlF, CernyA, CeredaJM, ZalaJF, HelblingB, SteuerwaldM, ZimmermannA. Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol, 4:1537–1543. 2006.
63.
EbiharaK, KusakabeT, HirataM, MasuzakiH, MiyanagaF. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab, 92:532–541. 2007.
64.
EkstromG, Ingelman-SundbergM. Rat liver microsomal NADPH supported oxidase activity and lipid peroxidation dependent on ethanolinducible cytochrome P-450 (P-450IIE1)Biochem Pharmacol, 38:1313–1319. 1989.
65.
ElsharkawyAM, MannDA. Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology, 46:590–597. 2007.
66.
EspositoE, IaconoA, BiancoG, AutoreG, CuzzocreaS, VajroP, CananiRB, CalignanoA, RasoGM, MeliR. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr, 139:905–911. 2009.
FeldsteinAE, CanbayA, AnguloP, TaniaiM, BurgartLJ, LindorKD, GoresGJ. Hepatocyte apoptosis and Fas expression are prominent features of human non-alcoholic steatohepatitis. Gastroenterology, 125:437–443. 2003.
69.
FleuryC, SanchisD. The mitochondrial uncoupling protein-2: current status. Int J Biochem Cell Biol, 31:1261–1278. 1999.
70.
FriedmanSL. Mechanisms of hepatic fibrogenesis. Gastroenterology, 134:1655–1669. 2008.
71.
FromentyB, PessayreD. Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther, 67:101–154. 1995.
72.
FujitaK, NozakiY, YonedaM, WadaK, TakahashiH, KirikoshiH, InamoriM, SaitoS, IwasakiT, TerauchiY, MaeyamaS, NakajimaA. Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model. Alcohol Clin Exp Res 34, S18–S24. 2010.
73.
FujitaK, YonedaM, WadaK, MawatariH, TakahashiH, KirikoshiH, InamoriM, NozakiY, MaeyamaS, SaitoS, IwasakiT, TerauchiY, NakajimaA. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci, 52:3455–3464. 2007.
74.
FukudaK, KojiroM, ChiuJF. Induction of apoptosis by transforming growth factor-β1 in the rat hepatoma cella line McA-RH7777: a possible association with tissue transglutaminase expression. Hepatology, 18:945–953. 1993.
75.
GaoD, WeiC, ChenL, HuangJ, YangS, DiehlAM. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol, 287:G1070–G1077. 2004.
76.
Garcia-RuizC, ColellA, MoralesA, KaplowitzN, Fernandez-ChecaJC. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Mol Pharmacol, 48:825–834. 1995.
77.
García-RuizI, Rodríguez-JuanC, Díaz-SanjuanT, del HoyoP, ColinaF, Muñoz-YagüeT, Solís-HerruzoJA. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology, 44:581–591. 2006.
78.
GaresseR, VallejoCG. Animal mitochondrial biogenesis and function: a regulatory cross-talk between two genomes. Gene, 263:1–16. 2001.
79.
GavrilovaO, HaluzikM, MatsusueK, CutsonJJ, JohnsonL, DietzKR, NicolCJ, VinsonC, GonzalezFJ, ReitmanML. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem, 278:34268–34276. 2003.
80.
GearingKL, GottlicherM, TeboulM, WidmarkE, GustafssonJA. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA, 90:1440–1444. 1993.
81.
GenovaM.L., BianchiC., LenazG.Supercomplex organization of the mitochondrial respiratory chain and the role of the coenzyme Q pool: pathophysiological implications. Biofactors, 25:5–20. 2005.
82.
GeorgescuEF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?Adv Ther, 25:1171–1174. 2008.
83.
GerthK, BedorfN, IrschikH, HofleG, ReichenbachH. The soraphens: a family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria). I. Soraphen A1 alpha: fermentation, isolation, biological properties. J Antibiot (Tokyo), 47:23–31. 1994.
84.
GiacchettiG, FaloiaE, SarduC, CamilloniMA, MarinielloB, GattiC. Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes Relat Metab Disord, 24,Suppl 2:S62–S143. 2000.
85.
GilksC.B., PriceK., WrightJ. L., ChurgA.Antioxidant gene expression in rat lung after exposure to cigarette smoke. Am J Pathol, 152:269–278. 1998.
86.
GlosliH, GudbrandsenOA, MullenAJ, HalvorsenB, RostTH, WergedahlH, PrydzH, AukrustP, BergeRK. Down-regulated expression of PPARa target genes, reduced fatty acid oxidation and altered fatty acid composition in the liver of mice transgenic for hTNFa. Biochim Biophys Acta, 1734:235–246. 2005.
87.
GorskyLD, KoopDR, CoonMJ. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. J Biol Chem, 259:62552–62557. 1984.
88.
GotohY, CooperJA. Reactive oxygen species-and dimerization induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem, 273:17477–17482. 1998.
89.
GrahamTL, MookherjeeC, SucklingKE, PalmerCN, PatelL. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(−/−) mice. Atherosclerosis, 181:29–37. 2005.
90.
GregorMF, YangL, FabbriniE. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes, 58:693–700. 2009.
91.
GuicciardiME, BronkSF, WerneburgNW, YinXM, GoresGJ. Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor α-induced hepatocyte apoptosis. Gastroenterology, 129:269–284. 2005.
92.
HaddadY, VallerandD, BraultA, HaddadPS. Evid Based Complement Alternat Med. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med, 2009[Epub ahead of print];DOI:10.1093/ecam/nep164.
93.
HalliwellB. Antioxidant defence mechanisms: from the beginning to the end (of the beginning)Free Radic Res, 31:261–272. 1999.
94.
HanKL, ChoiJS, LeeJY. Therapeutic potential of peroxisome proliferators: activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes, 57:737–745. 2008.
95.
HanssonT, TindbergN, Ingelman-SundbergM, KohlerC. Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience, 34:451–463. 1990.
96.
HaqueM, MirshahiF, Campbell-SargentC, SterlingRK, LuketicVA, ShiffmanVA. Nonalcoholic steatohepatitis (NASH) is associated with hepatocyte mitochondrial DNA depletion. Hepatology, 36:403A. 2002.
97.
HaradaN, OdaZ, HaraY, FujinamiK, OkawaM, OhbuchiK, YonemotoM, IkedaY, OhwakiK, AraganeK, TamaiY, KusunokiJ. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol Cell Biol, 27:1881–1888. 2007.
98.
HarrisonSA, TorgersonS, HayashiP, WardJ, SchenkerS. Vitamin E and Vitamin C Treatment Improves Fibrosis in Patients With Nonalcoholic Steatohepatitis. Am J Gastroenterol, 98:2485–2490. 2003.
HiguchiN, KatoM, ShundoY. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res, 38:1122–1129. 2008.
105.
Himms-HagenJ, HarperME. Physiological role of UCP-3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Exp Biol Med, 226:78–84. 2001.
106.
HiroseA, OnoM, SaibaraT, NozakiY, MasudaK, YoshiokaA, TakahashiM, AkisawaN, IwasakiS, ObenJA, OnishiS. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology, 45:1375–1381. 2007.
107.
HoffmeisterA, RothenbacherD, BaznerU, FrohlichM, BrennerH, HombachV, KoenigW. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol, 87:262–266. 2001.
108.
Holgado-MadrugaM, WongAJ. Gab1 is an integrator of cell death versus cell survival signals in oxidative stress. Mol Cell Biol, 23:4471–4484. 2003.
109.
HollienJ, WeissmanJS. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science, 313:104–107. 2006.
110.
HouglumK, VenkataramaniA, LycheK, ChojkierM. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology, 113:1069–1073. 1997.
111.
IchijoH, NishidaE, IrieK, ten DijkeP, SaitohM, MoriguchiT, TakagiM, MatsumotoK, MiyazonoK, GotohY. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science, 275:90–94. 1997.
112.
IkuraY, OhsakaM, FukushimaM, ShimadaM, RyoY, MuraguchiT, HirayamaM, SuekaneT, SugamaY, KawadaN, SekiS, UedaM. Increased expression of the scavenger receptor CD36 in activated stellate cells in steatotic livers; its relation to fibrotic process in nonalcoholic fatty liver disease. Hepatology, 42,S1:620A. 2005.
113.
ImaiH, NakagawaY. Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med, 34:145–169. 2003.
114.
InoshitaS, TakedaK, HataiT, TeradaY, SanoM, HataJ, UmezawaA, IchijoH. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem, 277:43730–43734. 2002.
115.
IresonC, OrrS, JonesDJ, VerschoyleR, LimCK, LuoJL, HowellsL, PlummerS, JukesR, WilliamsM, StewardWP, GescherA. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res, 61:1058–1064. 2001.
116.
IshiiS, IizukaK, MillerBC, UyedaK. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci USA, 101:15597–15602. 2004.
117.
IsodaK, OhsuzuF. The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. J Atheroscler Thromb, 13:21–30. 2006.
118.
JaburekM, VarechaM, GimenoRE, DembskiM, JezekP, ZhangM, BurnP, TartagliaLA, GarlidKD. Transport function and regulation of mitochondrial uncoupling proteins 2 and 3. J Biol Chem, 274:26003–26007. 1999.
119.
JezekP. Possible physiological roles of mitochondrial uncoupling proteins-UCPn. Int J Biochem Cell Biol, 34:1190–1206. 2002.
120.
JiC, KaplowitzN. ER stress: can the liver cope?J Hepatol, 45:321–333. 2006.
121.
JiangXC, LiZ, LiuR, YangXP, PanM, LagrostL, FisherEA, WilliamsKJ. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem, 280:18336–18340. 2005.
122.
JoH, ShimJ, LeeJH. IRE-1 and HSP-4 contribute to energy homeostasis via fasting-induced lipases in C. elegans. Cell Metab, 9:440–448. 2009.
123.
JohanssonI, LindrosKO, ErikssonH. Ingelman-Sundberg, M. Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochem Biophys Res Commun, 173:331–338. 1990.
124.
KakimotoM, InoguchiT, SontaT, YuHY, ImamuraM, EtohT, HashimotoT, NawataH. Accumulation of 8-hydroxy-2′-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes, 51:1588–1595. 2002.
125.
KamataH, HondaS, MaedaS, ChangL, HirataH, KarinM. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell, 120:649–661. 2005.
126.
KammounHL, ChabanonH, HainaultI. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest, 119:1201–1215. 2009.
127.
KangQ, ChenA. Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab Invest, 89:1275–1290. 2009.
128.
KangX, ZhongW, LiuJ, SongZ, McClainCJ, KangYJ, ZhouZ. Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Hepatology, 50:1241–1250. 2009.
LaethemRM, BalazyM, FalckJR, LaethemCL, KoopDR. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem, 268:12912–12918. 1993.
138.
LambJA, VenturaJJ, HessP, FlavellRA, DavisRJ. JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell, 11:1479–1489. 2003.
139.
LanderHM. An essential role for free radicals and derived species in signal transduction. FASEB J, 11:118–124. 1997.
140.
LavineJE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr, 136:734–738. 2000.
141.
LeclercqIA, FarrellGC, FieldJ, BellDR, GonzalezFJ, RobertsonGR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest, 105:1067–1075. 2000.
142.
LeclercqIA, FarrellGC, SchriemerR, RobertsonGR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol, 37:206–213. 2002.
143.
LeclercqIA, FarrellGC, SempouxC, dela PeñaA, HorsmansY. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol, 41:926–934. 2004.
144.
LeeAH, ScapaEF, CohenDE, GlimcherLH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science, 320:1492–1496. 2008.
145.
LeeCH, ParkSW, KimYS, KangSS, KimJA, LeeSH, LeeSM. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice. Biol Pharm Bull, 30:1898–1904. 2007.
146.
LeeJH, ChanJL, SourlasE, RaptopoulosV, MantzorosCS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab, 91:2605–2611. 2006.
147.
LeiK, DavisRJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA, 100:2432–2437. 2003.
148.
LeonardSS, XiaC, JiangBH, StinefeltB, KlandorfH, HarrisGK, ShiX. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun, 309:1017–1026. 2003.
LiZ, BerkM, McIntyreTM, GoresGJ, FeldsteinAE. The lysosomal-mitochondrial axis in free fatty acid–induced hepatic lipotoxicity. Hepatology, 47:1495–1503. 2008.
151.
LiangH, WardWF. PGC-1α: a key regulator of energy metabolism. Adv Physiol Educ, 30:145–151. 2006.
152.
LiangLJ, YinXY, LuoSM, ZhengJF, LuMD, HuangJF. A study of the ameliorating effects of carnitine on hepatic steatosis induced by total parenteral nutrition in rats. World J Gastroenterol, 5:34–315. 1999.
153.
LieberCS. Cytochrome P4502E1: its physiological and pathological role. Physiol Rev, 77:517–544. 1997.
154.
LimHJ, ParkJH, LeeS, ChoiHE, LeeKS, ParkHY. PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. Eur J Pharmacol, 622:45–51. 2009.
155.
LinJ, WuPH, TarrPT, LindenbergKS, St PierreJ, ZhangCY, MoothaVK, JagerS, ViannaCR, ReznickRM, CuiL, ManieriM, DonovanMX, WuZ, CooperMP, FanMC, RohasLM, ZavackiAM, CintiS, ShulmanGI, LowellBB, KraincD, SpiegelmanBM. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, 119:121–135. 2004.
LiuH, LoCR, CzajaMJ. NF-B inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology, 35:772–778. 2002.
158.
LiuY, MinW. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activityindependent manner. Circ Res, 90:1259–1266. 2002.
159.
LoguercioC, FedericoA, TrappoliereM, TuccilloC, de SioI, Di LevaA, NiosiM, D'AuriaMV, CapassoR, Del Vecchio BlancoC. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci, 52:2387–2395. 2007.
160.
LoidaPJ, SligarSG. Molecular recognition in cytochrome P-450: mechanism for the control of uncoupling reactions. Biochemistry, 32:11530–11538. 1993.
MarxN, SukhovaG, CollinsT, LibbyP, PlutzkyJ. PPAR-activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 99:345–3131. 1999.
173.
MatteyDL, HassellAB, DawesPT, JonesPW, YengiL, AllderseaJ, StrangeRC, FryerAA. Influence of polymorphism in the manganese superoxide dismutase locus on disease outcome in rheumatoid arthritis: evidence for interaction with glutathione S-transferase genes. Arthritis Rheum, 43:859–864. 2000.
McGarryJD, FosterDW. Regulation of hepatic fatty acid oxidation and ketone body production. Ann Rev Biochem, 49:395–420. 1980.
176.
MemonRA, TecottLH, NonogakiK, BeigneuxA, MoserAH, GrunfeldC, FeingoldKR. Up-regulation of peroxisome proliferator-activated receptors (PPAR-a) and PPAR-g messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-g-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology, 41:4021–4031. 2000.
177.
MicheauO, TschoppJ. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 117:181–190. 2003.
178.
MimaniM, HirasawaT, ItohY, OkanoueT. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int, 26:613–620. 2006.
179.
MinokoshiY, KimYB, PeroniOD, FryerLG, MullerC. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature, 415:339–343. 2002.
180.
MitrunenK, SillanpääP, KatajaV, EskelinenM, KosmaVM, BenhamouS, UusitupaM, HirvonenA. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis, 22:827–829. 2001.
181.
MussoG, GambinoR, CassaderM. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev, 11:430–445. 2009.
182.
MussoG, GambinoR, De MichieliF, BiroliG, FagàE, PaganoG, CassaderM. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Ann Med, 40:383–94. 2008.
183.
MussoG, GambinoR, De MichieliF, BiroliG, PremoliA, PaganoG, BoS, DurazzoM, CassaderM. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr, 86:661–71. 2007.
184.
MussoG, GambinoR, DurazzoM, BiroliG, CarelloM, FagaE, PaciniG, De MichieliF, RabbioneL, PremoliA, CassaderM, PaganoG. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology, 42:1175–1183. 2005.
185.
MussoG, GambinoR, PaciniG, PaganoG, DurazzoM, CassaderM. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology, 49:426–435. 2009.
186.
NagasawaT, InadaY, NakanoS, TamuraT, TakahashiT, MaruyamaK, YamazakiY, KurodaJ, ShibataN. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-defi cient diet. Eur J Pharmacol, 536:182–190. 2006.
187.
NagasawaT, NakanoS, IjiroT, InadaY, TamuraT, MaruyamaK, KurodaJ, YamazakiY, KusamaH, ShibataN. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol Res, 38:1026–1239. 2008.
188.
NakagawaT, ZhuH, MorishimaN, LiE, XuJ, YanknerBA, YuanJ. Caspase-12 mediates endoplasmic- reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature, 403:98–103. 2000.
189.
NakataniT, KatsumataA, MiuraS, KameiY, EzakiO. Effects of fish oil feeding and fasting on LXR alpha/RXRalpha binding to LXRE in the SREBP-1c promoter in mouse liver. Biochim Biophys Acta, 1736:77–86. 2005.
190.
NamikawaC, Shu-PingZ, VyselaarJR, NozakiY, NemotoY, OnoM, AkisawaN, SaibaraT, HiroiM, EnzanH, OnishiS. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol, 40:781–786. 2004.
191.
NeveEP, Ingelman-SundbergM. Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1)J Biol Chem, 276:11317–11322. 2001.
192.
NeveEP, Ingelman-SundbergM. Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane. J Biol Chem, 275:17130–17135. 2000.
193.
NeveEP, HidestrandM, Ingelman-SundbergM. Identification of sequences responsible for intracellular targeting and membrane binding of rat CYP2E1 in yeast. Biochemistry, 42:14566–14575. 2003.
194.
NietoN. Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells. Hepatology, 44:1487–1501. 2006.
195.
NomiyamaT, TanakaY, PiaoL, NagasakaK, SakaiK, OgiharaT, NakajimaK, WatadaH, KawamoriR. The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet, 48:138–141. 2003.
196.
NordbergJ, ArnerES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med, 31:1287–1312. 2001.
197.
Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell, 97:161–163. 1999.
198.
OdegaardJI, Ricardo-GonzalezRR, Red EagleA, VatsD, MorelCR, GoforthMH, SubramanianV, MukundanL, FerranteAW, ChawlaA. Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity- induced insulin resistance. Cell Metab, 7:496–507. 2008.
199.
OhSY, ParkSK, KimJW, AhnYH, ParkSW, KimKS. Acetyl-CoA carboxylase beta gene is regulated by sterol regulatory element-binding protein-1 in liver. J Biol Chem, 278:28410–28417. 2003.
200.
OkadaK, HiranoT, RanJ, AdachiM. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res, 27:293–299. 2004.
201.
OlmosA, GinerRM, MáñezS. Drugs modulating the biological ejects of peroxynitrite and related nitrogen species. Med Res Rev, 27:1–64. 2007.
202.
OrellanaM, RodrigoR, VarelaN, ArayaJ, PoniachikJ, CsendesA, SmokG, VidelaLA. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatology Res, 34:57–63. 2006.
203.
OstA, DanielssonA, LidenM, ErikssonU, NystromFH, StrålforsP. Retinol binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J, 21:3696–3704. 2007.
204.
OtaT, GayetC, GinsbergHN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest, 118:316–332. 2008.
205.
OyadomariS, HardingHP, ZhangYH. Dephosphorylation of translation initiation factor 2 alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab, 7:520–532. 2008.
206.
PaganoC, SoardoG, PilonC, MiloccoC, BasanL, MilanG, DonniniD, FaggianD, MussapM, PlebaniM, AvelliniC, FederspilG, SechiLA, VettorR. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab, 91:1081–1086. 2006.
207.
PanM, CederbaumAI, ZhangYL, GinsbergHN, WilliamsKJ, FisherEA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest, 113:1277–1287. 2004.
208.
PaolissoG, D'AmoreA, GiuglianoD, CerielloA, VarricchioM, D'OnofrioF. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr, 57:650–656. 1993.
209.
ParolaM, LeonarduzziG, BiasiF, AlbanoE, BioccaME, PoliG, DianzaniMU. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology, 16:1014–1021. 1992.
210.
PatersonJM, MortonNM, FievetC, KenyonCJ, HolmesMC, StaelsB. Metabolic syndrome without obesity: hepatic overexpression of 11-b-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA, 101:7088–7093. 2004.
211.
PengHM, CoonMJ. Regulation of rabbit cytochrome P450 2E1 expression in HepG2 cells by insulin and thyroid hormone. Mol Pharmacol, 54:740–747. 1998.
212.
Perez-CarrerasM, del HoyoP, MartinMA. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 38:999–1007. 2003.
213.
PessayreD, FromentyB. NASH: a mitochondrial disease. J Hepatol, 42:928–940. 2005.
214.
PessayreD, MansouriA, FromentyB. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol, 282:G193–G199. 2002.
215.
PettaS, CammàC, Di MarcoV, AlessiN, BarbariaF, CabibiD, CaldarellaR, CiminnisiS, LicataA, MassentiMF, MazzolaA, TarantinoG, MarchesiniG, CraxìA. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology, 48:28–37. 2008.
216.
PflugerPT, HerranzD, Velasco-MiguelS, SerranoM, TschöpMH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA, 105:9793–9798. 2008.
217.
PhamCG, BubiciC, ZazzeroniF, PapaS, JonesJ, AlvarezK, JayawardenaS, DeSE, CongR, BeaumontC, TortiFM, TortiSV, FranzosoG. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell, 119:529–542. 2004.
218.
PinzaniM, MarraF. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis, 21:397–416. 2001.
219.
PlanavilaA, LagunaJC, Vazquez-CarreraM. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem, 280:17464–17471. 2005.
220.
PolyakSJ, MorishimaC, ShuhartMC, WangCC, LiuY, LeeDY. Inhibition of T-cell inflammatory cytokines, hepatocyte NFkappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology, 132:1925–1936. 2007.
221.
PospisilikJA, KnaufC, JozaN, BenitP, OrthoferM, CaniPD, EbersbergerI, NakashimaT, SaraoR, NeelyG, EsterbauerH, KozlovA, KahnCR, KroemerG, RustinP, BurcelinR, PenningerJM. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell, 131:476–491. 2007.
222.
PosticC, GirardJ. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest, 118:829–838. 2008.
223.
PuigserverP, WuZ, ParkCW, GravesR, WrightM, SpiegelmanBM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 92:829–839. 1998.
224.
PuriP, MirshahiF, CheungO, NatarajanR, MaherJW, KellumJM, SanyalAJ. Activation and dysregulation of the unfolded protein response in nonalcoholic datty liver disease. Gastroenterology, 134:568–576. 2008.
RaoRV, HermelE, Castro-ObregonS, del RioG, EllerbyLM, EllerbyHM, BredesenDE. Coupling endoplasmic reticulum stress to the cell death program: mechanism of caspase activation. J Biol Chem, 276:33869–33874. 2001.
233.
RaucyJL, LaskerJM, KranerJC, SalazarDE, LieberCS, CorcoranGB. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol, 39:275–280. 1991.
234.
ReddyJK, HashimotoT. Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: an adaptive metabolic system. Annu Rev Nutr, 21:193–230. 2001.
235.
ReddyJK, RaoMS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol, 290:G852–G858. 2006.
236.
ReddyJK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Physiol, 281:G1333–G1339. 2001.
237.
RensenSS, SlaatsY, NijhuisJ, JansA, BieghsV, DriessenA, MalleE, GreveJW, BuurmanWA. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol, 175:1473–1482. 2009.
238.
RepaJJ, LiangG, OuJ, BashmakovY, LobaccaroJM, ShimomuraI, ShanB, BrownMS, GoldsteinJL, MangelsdorfDJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev, 14:2819–2830. 2000.
239.
RigazioS, LehtoHR, TuunanenH, NågrenK, KankaanpaaM, SimiC, BorraR, NaumAG, ParkkolaR, KnuutiJ, NuutilaP, IozzoP. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans. Am J Physiol Endocrinol Metab, 295:E413–E419. 2008.
240.
RobertsLD, HassallDG, WinegarDA, HaseldenJN, NichollsAW, GriffinJL. Increased hepatic oxidative metabolism distinguishes the action of peroxisome proliferator-activated receptor delta from peroxisome proliferator-activated receptor gamma in the Ob/Ob mouse. Genome Med, 1:115. 2009.
241.
RobertsRA, LaskinDL, SmithCV, RobertsonFM, AllenEM, DoornJA, SlikkerW. Nitrative and oxidative stress in toxicology and disease. Toxicol Sci, 112:4–16. 2009.
SakonS, XueX, TakekawaM, SasazukiT, OkazakiT, KojimaY, PiaoJH, YagitaH, OkumuraK, DoiT, NakanoH. NFkappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J, 22:3898–3909. 2003.
250.
SalviM, BattagliaV, BrunatiAM, La RoccaN, TibaldiE, PietrangeliP, MarcocciL, MondoviB, RossiCA, ToninelloA. Catalase takes part in rat liver mitochondria oxidative stress defense. J Biol Chem, 282:24407–24415. 2007.
251.
SanyalAJ, Campbell-SargentC, MirshahiF, RizzoWB, ContosMJ, SterlingRK, LuketicVA, ShiffmanML, CloreJN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 120:1183–1192. 2001.
252.
SanyalAJ, ChalasaniN, KowdleyKV, McCulloughA, DiehlAM, BassNM, Neuschwander-TetriBA, LavineJE, TonasciaJ, UnalpA, Van NattaM, ClarkJ, BruntEM, KleinerDE, HoofnagleJH, RobuckPR. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med, 362:1675–1685. 2010.
253.
SasazukiT, OkazakiT, TadaK, Sakon-KomazawaS, KatanoM, TanakaM, YagitaH, OkumuraK, TominagaN, HayashizakiY, OkazakiY, NakanoH. Genome wide analysis of TNF-inducible genes reveals that antioxidant enzymes are induced by TNF and responsible for elimination of ROS. Mol Immunol, 41:547–551. 2004.
254.
SavageDB, ChoiCS, SamuelVT, LiuZX, ZhangD, WangA, ZhangXM, ClineGW, YuXX, GeislerJG, BhanotS, MoniaBP, ShulmanGI. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest, 116:817–824. 2006.
255.
SaxenaNK, IkedaK, RockeyDC, FriedmanSL, AnaniaFA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology, 35:762–71. 2002.
256.
ScarpullaRC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta, 1576:1–14. 2002.
257.
SchattenbergJM, SinghR, WangY, LefkowitchJH, RigoliRM, SchererPE, CzajaMJ. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology, 43:163–172. 2006.
258.
SchneiderhanW, Schmid-KotsasA, ZhaoJ, GrünertA, NüsslerA, WeidenbachH, MenkeA, SchmidRM, AdlerG, BachemMG. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology, 34:729–737. 2001.
259.
SchreursM, KuipersF, van der LeijFR. Regulatory enzymes of mitochondrial β-oxidation as targets for treatment of the metabolic syndrome. Obesity Rev, 11:380–388. 2010.
260.
SchreursM, Van DijkTH, GerdingA, HavingaR, ReijngoudDJ, KuipersF. Soraphen. An inhibitor of the acetyl-CoA carboxylase system improves peripheral insulin sensitivity in mice fed a high-fat diet. Diabetes Obes Metab, 11:987–991. 2009.
261.
SchroderM, KaufmanRJ. The mammalian unfolded protein response. Annu Rev Biochem, 74:739–789. 2005.
262.
SchwabeRF, BrennerDA. Mechanisms of liver injury. I. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol, 290:G583–G589. 2006.
263.
SchwabeRF, UchinamiH, QianT, BennettBL, LemastersJJ, BrennerDA. Differential requirement for c-Jun NH2-terminal kinase in TNF- and Fas-mediated apoptosis in hepatocytes. FASEB J, 18:720–722. 2004.
264.
SenCK, KhannaS, RoyS. Tocotrienols: vitamin E beyond tocopherols. Life Sci, 78:2088–608. 2006.
ShenHM, LinY, ChoksiS, TranJ, JinT, ChangL, KarinM, ZhangJ, LiuZG. Essential roles of receptor-interacting protein and TRAF2 in oxidative stress-induced cell death. Mol Cell Biol, 24:5914–5922. 2004.
269.
ShenY, VolrathSL, WeatherlySC, ElichTD, TongL. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol Cell, 16:881–891. 2004.
SinghR, WangY, XiangY, TanakaKE, GaardeWA, CzajaMJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology, 49:87–96. 2009.
272.
SnappE. Endoplasmic reticulum biogenesis proliferation and differentiation. The Biogenesis of Cellular Organellesedited byMullinsC. New York: Kluwer Academic/Plenum Publishers, 2005; 63–95.
273.
SodenJS, DevereauxMW, HaasJE, GumprichtE, DahlR, GrallaJ, TraberMG, SokolRJ. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatohepatitis. Hepatology, 46:485–495. 2007.
274.
SohetFM, NeyrinckAM, PachikianBD, de BackerFC, BindelsLB, NiklowitzP, MenkeT, CaniPD, DelzenneNM. Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol, 78:1391–1400. 2009.
275.
SokolRJ, McKimJMJr., GoffMC, RuyleSZ, DevereauxMW, HanD, PackerL, EversonG. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology, 117:164–174. 1998.
276.
SongJJ, LeeYJ. Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal regulating kinase 1. Biochem J, 373:845–853. 2003.
277.
SongJJ, RheeJG, SuntharalingamM, WalshSA, SpitzDR, LeeYJ. Role of glutaredoxin in metabolic oxidative stress: glutaredoxin as a sensor of oxidative stress mediated by H2O2. J Biol Chem, 277:46566–46575. 2002.
278.
SorianoME, NicolosiL, BernardiP. Desensitization of the permeability transition pore by cyclosporin a prevents activation of the mitochondrial apoptotic pathway and liver damage by tumor necrosis factor-αJ Biol Chem, 279:36803–36808. 2004.
279.
SreejayanN, DongF, KandadiMR, YangX, RenJ. Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity, 16:1331–1337. 2008.
280.
SrinivasanM, KatewaSD, PalaniyappanA, PandyaJD, PatelMS. Maternal high-fat diet consumption results in fetal malprogramming predisposing to the onset of metabolic syndrome-like phenotype in adulthood. Am J Physiol Endocrinol Metab, 291:E792–E799. 2006.
281.
StefanN, HennigeAM, StaigerH, MachannJ, SchickF, SchleicherE, FritscheA, HäringHU. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care, 30:1173–1178. 2007.
282.
StewartSF, LeathartJB, ChenY, DalyAK, RollaR, VayD, MottaranE, VidaliM, AlbanoE, DayCP. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology, 36:1355–1360. 2002.
283.
StoehlmacherJ, InglesSA, ParkDJ, ZhangW, LenzHJ. The −9Ala/−9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma. Oncol Rep, 9:235–238. 2002.
284.
StraussRS. Comparison of serum concentrations of a-tocopherol and b-carotene in a cross-sectional sample of obese and nonobese children (NHANES III)J Pediatr, 134:160–165. 1999.
285.
SuginoH, KumagaiN, WatanabeS, TodaK, TakeuchiO, TsunematsuS, MorinagaS, TsuchimotoK. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol, 23:1909–1916. 2008.
286.
SunX, HanR, WangZ, ChenY. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Diabetologia, 49:161–1310. 2006.
287.
TakahashiS, TanakaT, KodamabT, SakaiJ. Peroxisome proliferator-activated receptor δ (PPARδ), a novel target site for drug discovery in metabolic syndrome. Pharmacological Research, 53:501–507. 2006.
288.
TanY, DourdinN, WuC, De VeyraT, ElceJS, GreerPA. Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. J Biol Chem, 281:16016–16024. 2006.
289.
TanakaE, TeradaM, MisawaS. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther, 25:165–175. 2000.
290.
TangY, ZhengS, ChenA. Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology, 150:3011–3020. 2009.
291.
TeschkeR, MorenoF, PetridesAS. Hepatic microsomal ethanol oxidizing system (MEOS): respective roles of ethanol and carbohydrates for the enhanced activity after chronic alcohol consumption. Biochem Pharmacol, 30:1745–1751. 1981.
292.
TianoT, BelardinelliR, CarnevaliP, PrincipiF, SeddauG, LittarruGP. Effect of Coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischemic heart disease. A double blind randomized controlled study. Eur Heart J, 28:2249–2255. 2007.
293.
TilgH, HotamisligilGS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology, 131:934–945. 2006.
294.
TimlinMT, ParksEJ. The temporal pattern of de novo lipogenesis in the postprandial state. Am J Clin Nutr, 81:35–42. 2005.
TomitaK, TamiyaG, AndoS, OhsumiK, ChiyoT, MizutaniA, KitamuraN, TodaK, KanekoT, HorieY, HanJY, KatoS, ShimodaM, OikeY, TomizawaM, MakinoS, OhkuraT, SaitoH, KumagaiN, NagataH, IshiiH, HibiT. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut, 55:415–424. 2006.
297.
ToyokuniS. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int, 49:91–102. 1999.
298.
TrappoliereM, CaligiuriA, SchmidM, BertolaniC, FailliP, VizzuttiF, NovoE, di ManzanoC, MarraF, LoguercioC, PinzaniM. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol, 50:1102–1111. 2009.
299.
TreadwayJL, McPhersonRK, PetrasSF, ShellyLD, FrederickKS, SagawaK, PerryDA, HarwoodHJ. Effect of the acetyl-CoA carboxylase inhibitor CP-640186 on glycemic control in diabetic ob/ob mice. Diabetes, 53,Suppl 2:162. 2004.
300.
TsurutaF, SunayamaJ, MoriY, HattoriS, ShimizuS, TsujimotoY, YoshiokaK, MasuyamaN, GotohY. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J, 23:1889–1899. 2004.
301.
UchiyamaS, ShimizuT, ShirasawaT. CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J Biol Chem, 281:31713–31719. 2006.
302.
UeharaT, Xi PengX, BennettB, SatohY, FriedmanG, CurrinR, BrennerDA, LemastersJ. c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation, 78:324–332. 2004.
303.
UranoF, WangX, BertolottiA, ZhangY. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science, 287:664–666. 2000.
304.
UstundagY, OzerIO, YeniduniaS. Oxidized low density lipoprotein in liver tissue samples of our NASH patients, alcoholic and chronic viral hepatitis cases. Gastroenterology, 57:203. 2002.
305.
Van der LeijFR, BloksVW, GrefhorstA, HoekstraJ, GerdingA, KooiK, GerbensF, TeMG, KuipersF. Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. Genomics, 90:680–689. 2007.
306.
Van der VeenBS, de WintherMP, HeeringaP, AugustoO, ChenJW, DaviesM, MaXL, MalleE, PignatelliP, RudolphT. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal, 11:2899–2937. 2009.
307.
VarelaNM, QuiñonesLA, OrellanaM, PoniachikJ, CsendesA, SmokG, RodrigoR, CáceresDD, VidelaLA. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic nonalcoholic steatohepatitis obese women. Biol Res, 41:81–92. 2008.
308.
VenturaJJ, CogswellP, FlavellRA, BaldwinASJr, DavisRJ. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev, 18:2905–2915. 2004.
309.
VercammenD, BeyaertR, DeneckerG, GoossensV, VanLG, DeclercqW, GrootenJ, FiersW, VandenabeeleP. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med, 187:1477–1485. 1998.
310.
VercammenD, BrouckaertG, DeneckerG, Van de CraenM, DeclercqW, FiersW, VandenabeeleP. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med, 188:919–930. 1998.
Vilar GomezE, Rodriguez De MirandaA, Gra OramasB, Arus SolerE, Llanio NavarroR, Calzadilla BertotL, Yasells GarciaA, Del Rosario Abreu VazquezM. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther, 30:999–1009. 2009.
WanCD, WangCY, LiuT, ChengR, WangHB. Alleviation of ischemia/reperfusion injury in ob/ob mice by inhibiting UCP-2 expression in fatty liver. World J Gastroenterol, 14:590–594. 2008.
315.
WangD, WeiY, PagliassottiMJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology, 147:943–951. 2006.
316.
WangWH, GregoriG, HullingerRL, AndrisaniOM. Sustained activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase pathways by hepatitis B virus X protein mediates apoptosis via induction of Fas/FasL and tumor necrosis factor (TNF) receptor 1/TNF-expression. Mol Cell Biol, 24:10352–10365. 2004.
WeiY, ClarkSE, MorrisEM, ThyfaultJP, UptergroveGM, Whaley-ConnellAT, FerrarioCM, SowersJR, IbdahJA. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol, 49:417–428. 2008.
319.
WeiY, ClarkSE, ThyfaultJP, UptergroveGM, LiW, Whaley-ConnellAT, FerrarioCM, SowersJR, IbdahJA. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol, 174:1329–1337. 2009.
320.
WeiY, WangD, GentileCL, PagliassottiMJ. Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells. Mol Cell Biochem, 331:31–40. 2009.
321.
WeltmanMD, FarrellGC, LiddleC. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology, 111:1645–1653. 1996.
322.
WeltmanMD, FarrellGC, HallP, Ingelman-SundbergM, LiddleC. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 27:128–133. 1998.
323.
WernerE. GTPases and reactive oxygen species: switches for killing and signalingJ Cell Sci, 117:143–153. 2004.
324.
WhiteRE. The involvement of free radicals in the mechanisms of monooxygenases. Pharmacol Ther, 49:21–42. 1991.
325.
WieckowskaA, PapouchadoBG, LiZ, LopezR, ZeinNN, FeldsteinAE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol, 103:1372–1379. 2008.
326.
WillsonTM, BrownPJ, SternbachDD, HenkeBR. The PPARs: from orphan receptors to drug discovery. J Med Chem, 43:527–550. 2000.
327.
WinderWW, HardieDG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol, 270:E299–E304. 1996.
328.
WispeJR, ClarkJC, BurhansMS, KroppKE, KorfhagenTR, WhitsettJA. Synthesis and processing of the precursor for human manganosuperoxide dismutase. Biochim Biophys Acta, 994:30–36. 1989.
329.
WoodcroftKJ, HafnerMS, NovakRF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology, 35:263–273. 2002.
330.
WoutersK, van GorpPJ, BieghsV, GijbelsMJ, DuimelH, LütjohannD, KerksiekA, van KruchtenR, MaedaN, StaelsB, van BilsenM, Shiri-SverdlovR, HofkerMH. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of NASH. Hepatology, 48:474–486. 2008.
331.
WuZ, PuigserverP, AnderssonU, ZhangC, AdelmantG, MoothaV, TroyA, CintiS, LowellB, ScarpullaRC, SpiegelmanBM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98:115–124. 1999.
332.
WullaertA, van LooG, HeyninckK, BeyaertR. Hepatic tumor necrosis factor signaling and nuclear factor-κB: effects on liver homeostasis and beyond. Endocr Rev, 28:365–386. 2007.
333.
XuA, WangY, KeshawH, XuLY, LamKS. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest, 112:91–100. 2003.
334.
XuC, YuC, LiY. Ischaemia-reperfusion injury in non-alcoholic steatohepatitis (NASH): a tough problem to cope with. Gut, 57:1631. 2008
335.
YamagishiS-I, EdelsteinD, DuX-L, KanedaY, GuzmánM, BrownleeM. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem, 276:25096–25100. 2001.
336.
YamaguchiK, YangL, McCallS, HuangJ, YuXX, PandeySK, BhanotS, MoniaBP, LiYX, DiehlAM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology, 45:1366–1374. 2007.
337.
YamamotoK, IchijoH, KorsmeyerSJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol, 19:8469–8478. 1999.
YasutakeK, NakamutaM, ShimaY, OhyamaA, MasudaK, HarutaN, FujinoT, AoyagiY, FukuizumiK, Yoshimoto, TakemotoR, MiyaharaT, HaradaN, HayataF, NakashimaM, EnjojiM. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol, 44:471–477. 2009.
344.
YeJ, RawsonRB, KomuroR. ER stress induces cleavage of membranebound ATF6 by the same proteases that process SREBPs. Mol Cell, 6:1355–1364. 2000.
345.
YesilovaZ, YamanH, OktenliC, OzcanA, UygunA, CakirE, SanisogluSY, ErdilA, AtesY, AslanM, MusabakU, ErbilMK, KaraerenN, DagalpK. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol, 100:850–855. 2005.
346.
YinM, GabeleE, WheelerMD, ConnorH, BradfordBU, DikalovaA, RusynI, MasonR, ThurmanRG. Alcohol-induced free radicals in mice: direct toxicants or signaling molecules?Hepatology, 34:935–942. 2001.
347.
YonedaM, HottaK, NozakiY, EndoH, TomenoW, WatanabeS, HosonoK, MawatariH, IidaH, FujitaK, TakahashiH, KirikoshiH, KobayashiN, InamoriM, KubotaK, ShimamuraT, SaitoS, MaeyamaS, WadaK, NakajimaA. Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res, 39:963–971. 2009.
348.
YonedaM, HottaK, NozakiY, EndoH, UchiyamaT, MawatariH, IidaH, KatoS, FujitaK, TakahashiH, KirikoshiH, KobayashiN, InamoriM, AbeY, KubotaK, SaitoS, MaeyamaS, WadaK, NakajimaA. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int, 29:1078–1085. 2009.
349.
YonedaM, HottaK, NozakiY, EndoH, UchiyamaT, MawatariH, IidaH, KatoS, HosonoK, FujitaK, YonedaK, TakahashiH, KirikoshiH, KobayashiN, InamoriM, AbeY, KubotaK, SaitoS, MaeyamaS, WadaK, NakajimaA. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)BMC Gastroenterol, 8:27. 2008.
350.
YonedaM, MawafariH, FujitaK. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol, 42:573–582. 2007.
351.
YonedaT, ImaizumiK, OonoK, YuiD, GomiF, KatayamaT, TohyamaM. Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptorassociated factor 2-dependent mechanism in response to the ER stress. J Biol Chem, 276:13935–13940. 2001.
352.
YooJS, NingSM, PantuckCB, PantuckEJ, YangCS. Regulation of hepatic microsomal cytochrome P450IIE1 level by dietary lipids and carbohydrates in rats. J Nutr, 121:959–965. 1991.
353.
YoonJC, PuigserverP, ChenG, DonovanJ, WuZ, RheeJ, AdelmantG, StaffordJ, KahnCR, GrannerDK, NewgardCB, SpiegelmanBM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature, 413:131–138. 2001.
354.
YoungT, CunninghamCC, BaileySM. Reactive oxygen species production by the mitochondrial respiratory chain in isolated rat hepatocytes and liver mitochondria: studies using myxothiazol. Arch Biochem Biophys, 405:65–72. 2002.
355.
YounossiZM, BaranovaA, ZieglerK, Del GiaccoL, SchlauchK, BornTL, ElarinyH, GorretaF, Van MeterA, YounoszaiA, OngJP, GoodmanZ, ChandhokeV. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology, 42:665–674. 2005.
356.
YuanM, KonstantopoulosN, LeeJ, HansenL, LiZW, KarinM, ShoelsonSE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IkkβScience, 293:1673–1677. 2001.
357.
ZelkoIN, MarianiTJ, FolzRJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med, 33:337–349. 2002.
358.
ZeydaM, StulnigTM. Adipose tissue macrophages. Immunol Lett, 112:61–67. 2007.
359.
ZhangK, ShenX, WuJ. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell, 124:587–599. 2006.
360.
ZhaoY, LiS, ChildsEE, KuharskyDK, YinXM. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-α-induced liver injury. J Biol Chem, 276:27432–27440. 2001.
361.
ZhengS, HoosL, CookJ, TetzloffG, DavisHJr., Van HeekM, HwaJJ. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol, 584:118–124. 2008.
362.
ZhouG, GoldenT, AragonIV, HonkanenRE. Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. J Biol Chem, 279:46595–46605. 2004.
363.
ZhouM, XuA, TamPK, LamKS, ChanL, HooRL, LiuJ, ChowKH, WangY. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology, 48:1087–1096. 2008.
364.
ZhouQG, ZhouM, HouFF, PengX. Asymmetrical dimethylarginine triggers lipolysis and inflammatory response via induction of endoplasmic reticulum stress in cultured adipocytes. Am J Physiol Endocrinol Metab, 296:E869–E878. 2009.
365.
ZhouZ, LiuJ, SongZ, McClainCJ, KangYJ. Zinc supplementation inhibits hepatic apoptosis in mice subjected to a long-term ethanol exposure. Exp Biol Med, 233:540–548. 2008.
